Preventive effect of PGI2, 7-oxo-PGI2 and 17-aza-PGF2 alpha derivate on the development of indomethacin-induced intestinal mucosal damage in rats.
Intestinal mucosal damage was produced in rats by the s.c. administration of indomethacin (10 mg/kg). The number and severity of the small intestinal mucosal lesions was recorded. Different doses of prostacyclin (PGI2), 7-oxo-PGI2 and 17-aza-PGF2 alpha (0.25-0.5-1.00 mg/kg) were given i.p. at the time of administration of indomethacin. The effects of these compounds were studied on the number and severity of the small intestinal mucosal lesions. It was shown that (1) all tested compounds inhibited the number and severity of the intestinal mucosal lesions, however, to different extent; (2) the inhibition of the development of small intestinal mucosal damage displayed a dose-response relationship; (3) 17-aza-PGF2 alpha was found to have the most potent effect on the development of the intestinal lesions as well as on the development of gastric mucosal damage produced by ethanol.
D000818:Animals; D015237:Dinoprost / Q000031:analogs & derivatives*; D011464:Epoprostenol / Q000494:pharmacology* / Q000031:analogs & derivatives; D007213:Indomethacin / Q000633:toxicity*; D007410:Intestinal Diseases / Q000139:chemically induced* / Q000517:prevention & control; D007413:Intestinal Mucosa / Q000187:drug effects*; D011461:Prostaglandins F, Synthetic / Q000494:pharmacology*; D051381:Rats; D014456:Ulcer / Q000139:chemically induced / Q000517:prevention & control
D011461:Prostaglandins F, Synthetic; C044962:17-azaprostaglandin F2alpha; C033705:7-oxoprostaglandin I2; D015237:Dinoprost; D011464:Epoprostenol; D007213:Indomethacin